ZIOPTAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZIOPTAN (ZIOPTAN).
ZIOPTAN (tafluprost) is a prostaglandin analog that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
| Metabolism | Metabolized by esterases in the eye to the active acid; further metabolism via beta-oxidation and reduction. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 70-80% of an administered dose recovered in urine over 48 hours); biliary/fecal excretion accounts for 13% to 20% as parent drug and metabolites. |
| Half-life | Terminal elimination half-life is approximately 2.8 to 4.5 hours in patients with normal renal function; no clinically significant accumulation occurs with twice-daily dosing. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is 0.92 ± 0.27 L/kg, indicating distribution into total body water with some tissue binding. |
| Bioavailability | Bioavailability after topical ocular administration is approximately 30% due to significant metabolism in the cornea and nasolacrimal system; systemic exposure is low. |
| Onset of Action | Onset of ocular hypotensive effect occurs within 1 to 2 hours after topical instillation; maximal effect is achieved at approximately 8 to 12 hours post-dose. |
| Duration of Action | Duration of action is at least 24 hours after a single topical dose, allowing once-daily administration; clinical effect persists for 24 hours with regular use. |
| Molecular Weight | 452.49 |
250 mg orally once daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | For GFR 30-89 mL/min: no adjustment; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B or C: not recommended. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific dose adjustment required; monitor renal function. |
| 1st trimester | ZIOPTAN (tafluprost) is contraindicated during pregnancy. Data from animal studies show reproductive toxicity including embryofetal lethality and malformations at clinically relevant doses. No adequate human studies exist. |
| 2nd trimester | Contraindicated in second trimester due to potential prostaglandin F2alpha analog effects on uterine contractility and fetal development. |
| 3rd trimester | Contraindicated in third trimester; may induce premature labor or affect fetal cardiovascular system. |
Clinical note
Comprehensive clinical and safety monograph for ZIOPTAN (ZIOPTAN).
| Placental transfer | Tafluprost undergoes hydrolysis to an active metabolite that can cross the placenta. Animal studies demonstrate placental transfer and accumulation in fetal tissues. |
| Breastfeeding | Tafluprost is excreted in animal milk. Although systemic exposure in humans is low after ophthalmic administration, due to the lack of human data, caution is advised. Discontinue drug or breastfeeding, taking into account importance to mother. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to tafluprost or any excipientPregnancy
| Precautions | May cause changes to pigmented tissues (e.g., iris, eyelids, eyelashes); use with caution in patients with intraocular inflammation (iritis/uveitis), aphakic/pseudophakic patients with torn posterior lens capsule, or those with risk factors for macular edema., May cause eyelash changes (increased length, thickness, pigmentation) and periorbital tissue changes., May reactivate ocular herpes simplex. |
| Food/Dietary | No clinically significant food interactions. Avoid excessive alcohol consumption as it may increase intraocular pressure fluctuations. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - limited human data; potential for adverse effects in infant. |
| Teratogenic Risk | ZIOPTAN (tafluprost ophthalmic solution) is a prostaglandin analog. Systemic exposure after ocular administration is minimal. However, prostaglandins can increase uterine tone and contractions. Based on animal studies and mechanism of action, there is a potential risk of abortion or preterm labor. Use in pregnancy is not recommended unless clearly necessary. In first trimester: avoid unless benefit outweighs risk; second/third trimesters: may cause uterine contractions; near term: risk of preterm labor. |
| Fetal Monitoring | Monitor for signs of preterm labor, uterine contractions, or vaginal bleeding during pregnancy. In neonates exposed in utero, no specific fetal monitoring required after delivery unless maternal complications occurred. Ocular effects in mother require routine ophthalmic exams. |
| Fertility Effects | No human data on fertility effects. In animal studies, tafluprost did not impair fertility. However, prostaglandin analogs may theoretically affect reproductive function; no evidence of significant impairment in clinical use. |
| Clinical Pearls |
| ZIOPTAN (tafluprost ophthalmic solution) is a prostaglandin analog for reducing intraocular pressure in open-angle glaucoma or ocular hypertension. Administer once daily in the evening; systemic absorption is minimal but may cause gradual iris darkening, eyelash changes, and periorbital fat atrophy. Monitor for macular edema in aphakic or pseudophakic patients with torn posterior lens capsule. Remove contact lenses before instillation and wait 15 minutes before reinserting. Avoid touching the tip to any surface to prevent contamination. |
| Patient Advice | Use exactly as prescribed: one drop in the affected eye(s) once daily in the evening. · Do not use more than once daily as it may reduce effectiveness. · Remove contact lenses before use and wait at least 15 minutes before reinserting. · Avoid touching the dropper tip to your eye or any surface to prevent infection. · Expect possible changes in eye color (darkening), eyelash growth/thickness, or skin darkening around the eyes; these are usually permanent. · Report any eye pain, vision changes, or redness lasting more than a few days. · If you miss a dose, use it as soon as remembered, but skip if almost time for the next dose; do not double up. · Store at 2-8°C (refrigerate) and protect from light; do not freeze. |